Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic cancer ...

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) saw its stock surge 400% after unveiling positive preclinical findings for its ...

PanTher Therapeutics announced that it has concluded dosing in the first cohort of its Phase 1b trial of PTM-101 in pancreatic ductal adenocarcinoma.

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces ...

First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –– Study explores ...

Columbus-based Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has launched a fully remote clinical trial for pancreatic ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back. “If you were to ask me what disease most needs something to prevent ...

Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...

Still, physicians so far are being careful with GLP-1s in oncology, particularly with pancreatic cancer patients or those ...

As a 12-year pancreatic cancer survivor, I share my journey through diagnosis, treatment and survival, hoping my story ...